Why "conscious, following commands" matters here

• GCS E4V5M6 tells you there is no CNS involvement yet - CCHF and other VHFs can progress to encephalopathy/seizures in severe cases, so this is currently reassuring and means the patient can protect his own airway.
• It does not mean he is out of danger. His trajectory in the notes (platelets crashing from initial values to 14,000, worsening lung involvement despite BiPAP, need for noradrenaline) shows this can decompensate fast, independent of mental status. Intubation decisions here would be driven by respiratory failure/oxygenation, not GCS.
• A patient who is talking and orientated is often (wrongly) treated as "stable" - the key teaching point is that VHF/CCHF patients can be conscious right up until sudden hemorrhagic or multiorgan collapse, so monitoring frequency should not be relaxed just because he's alert.

Further management, given "history of bite" (suspected tick-borne CCHF)

• Strict contact/droplet isolation, dedicated PPE (gloves, gown, eye protection) for anyone handling blood, secretions, or sharps - CCHF spreads readily via blood/body fluid exposure and needlestick, including nosocomial outbreaks (Harrison's Principles of Internal Medicine 22E).
• Notify public health/infectious disease authorities - CCHF is a notifiable viral hemorrhagic fever.

• IV ribavirin, started as early as possible, is the only therapy with reported (anecdotal-to-moderate) benefit in CCHF (Goldman-Cecil Medicine; Harrison's 22E). Your note explicitly says "Ribavirin ordered but not available" - this is the single biggest treatable gap in this case and should be escalated/sourced urgently, ideally before transfer.

• Platelet transfusion (as already given - RDP/SDP) guided by platelet count and active bleeding, plus FFP/cryoprecipitate if there's DIC or fibrinogen depletion.
• Avoid unnecessary IM injections, arterial punctures, or invasive lines unless essential, given bleeding risk.

• Noradrenaline for shock, BiPAP/escalate to invasive ventilation if oxygenation worsens (guided by ABG/SpO2, not consciousness).
• Renal and liver function monitoring - CCHF causes transaminitis and can progress to renal dysfunction.
• Broad-spectrum antibiotics should continue to cover concurrent/superimposed bacterial sepsis (the meropenem/doxycycline/clindamycin regimen already covers atypical and possible rickettsial/brucella co-infection, reasonable given the weakly positive Brucella IgM).

• The left foot swelling/redness (bite site) needs local wound care and monitoring for secondary cellulitis; tetanus prophylaxis should be confirmed/given if status is unknown.

• Send CCHF RT-PCR/serology to a reference lab if not already done, and correlate the "weakly positive" Brucella IgM clinically - it may be incidental/cross-reactive rather than the primary driver of this presentation.

• Continue ribavirin (if sourced), inotropes, and ventilatory support en route.
• Transport team needs the same barrier precautions as the ICU staff, given ongoing bleeding/blood exposure risk during a high-risk transfer.

Recent literature check

Further Management - Suspected CCHF with ARDS / Septic Shock / MODS

• India's NCDC and WHO guidance support prompt ribavirin, though the WHO fact sheet is explicit that evidence for efficacy is uncertain and dosing is not fully standardized - use it as best-available therapy, not a guaranteed cure.
• Commonly used oral regimen (WHO/India NCDC/Pakistan NIH protocols): 2 g loading dose, then 4 g/day in 4 divided doses (6-hourly) for 4 days, followed by 2 g/day in 4 divided doses for 6 days. IV ribavirin (derived from Lassa fever dosing) is an alternative if oral is not tolerated or the patient can't take enteral medication (Goldman-Cecil Medicine).
• A 2025 analysis (Medscape/PubMed) found ribavirin given within 96 hours of symptom onset was linked to lower mortality - by day 5-6 of illness here, benefit is uncertain but still reasonable to give if sourced, given ongoing deterioration.
• If ribavirin truly cannot be sourced locally, this should be escalated as a priority for the receiving/higher center, and documented clearly in the transfer letter.

• Platelet transfusion: general threshold for prophylactic platelets in a non-bleeding patient is <10,000-20,000/mm3; for a patient with active/high bleeding risk (ICU, invasive lines, possible DIC) the threshold is higher, often <30,000-50,000/mm3. At a count of 14,000 with severe systemic illness, continued platelet support (RDP/SDP) alongside FFP/cryoprecipitate is appropriate if there is any oozing, mucosal bleeding, or coagulopathy on labs (PT/APTT/fibrinogen/D-dimer).
• Avoid arterial punctures, IM injections, unnecessary line changes - each is a bleeding and staff-exposure risk in VHF.

• Continue lung-protective strategy: low tidal volume ventilation (~6 mL/kg predicted body weight), plateau pressure <30 cmH2O, conservative fluid management (Murray & Nadel's Textbook of Respiratory Medicine).
• If P/F ratio falls below ~150 despite BiPAP/optimized settings, escalate to invasive ventilation with consideration of prone positioning (>16 hrs/day shown to have mortality benefit in severe ARDS) - this decision is independent of his conscious/oriented status, which only tells you he can still protect his airway right now, not that his lungs are stable.
• Therapeutic (not large-volume) drainage of pleural effusions only if compromising oxygenation/ventilation, weighed against bleeding risk from the procedure itself.

• Continue noradrenaline titrated to MAP target (~65 mmHg), reassess volume status frequently since aggressive crystalloids can worsen capillary leak/pulmonary edema in VHF - conservative fluid strategy is preferred once perfusion is adequate.
• Daily monitoring of renal function, liver enzymes (AST/ALT), CPK, and coagulation profile - CCHF characteristically causes transaminitis and can progress to hepatic and renal dysfunction as part of MODS.

• Maintain strict contact/droplet precautions and PPE for all staff handling blood, secretions, or the transport team - CCHF nosocomial spread is well documented via blood exposure and needlesticks.
• Report to public health authorities as a notifiable viral hemorrhagic fever; send confirmatory CCHF RT-PCR/serology to the reference lab if not already sent.
• If any healthcare worker has an unprotected blood/body fluid exposure, postexposure ribavirin prophylaxis should be considered (reported regimens: 1,200-4,000 mg/day in 2-4 divided doses for 5-14 days).

• Since the family is taking him against medical advice: document clearly that risks of high-risk inter-facility transport were explained (hemodynamic instability, risk of deterioration/death en route, need for isolation during transfer).
• Ensure the transferring ambulance is ICU-equipped (ventilator/BiPAP capability, inotrope infusion pump, PPE supplies for the crew) and that the receiving center is pre-notified of the working diagnosis so isolation and ribavirin can be arranged immediately on arrival.
• Hand over all investigations, the IgM Brucella and any CCHF test results, and a clear medication/dose list (as already documented) to avoid treatment gaps during transfer.